CommsRx
The AI-Era Operating System for Pharma and Biotech Communications Teams
Meet Ally: the AI strategist built exclusively for biopharma comms.
- 16 playbooks, from Phase 3 readouts to LOE
- Patent-pending message fingerprinting by meaning
- Media + AI radar
Reclaim the hours lost to tedious work like MLR prep and follow-up, and give your leaders room to drive commercial impact.
Thanks. Someone from CommsRx will be in touch to arrange your demo.
That request didn’t go through. Please try again.
We use this request to arrange your demonstration. Demo request privacy notice
One colleague.
Every desk in the work.
The experience behind blockbuster brands. Now behind your team.
How CommsRx works · Ally, at every desk
From the first question to what the market heard.
CommsRx carries a pivotal business moment through three phases, with Ally at every desk: find the strategy, carry the approved message into every material, and release it to the people your audiences trust.
Find the strategy before the first draft.
Approve once. Carry it wherever it’s in scope.
Release it in your name. See what landed.
01 · Ally · find the strategy
An AI strategist with decades of high-stakes pharma and biotech communications judgment.
Ally is an AI agent running on frontier intelligence and guided by a communications cognition system: the way a senior pharma strategist thinks, built into how she works.
Diagnoses before she drafts
Every brief starts with the market, read through four lenses: your differentiator, the unmet need, the white space and the trusted intermediary.
Starts with the business
Commercial objective, communications objective, plan backwards, prove it.
Knows the moment
Sixteen situation playbooks, from Phase 3 readouts and PDUFA dates to crises, deals and loss of exclusivity.
Carries the tradecraft
Judgment cards hold a senior practitioner’s instincts and come forward when the moment calls for them.
Speaks your field
Built-in domain expertise for pharma, biotech and medtech.
Learns how you decide
Every call you make, with your reason, sharpens her next recommendation.
16 playbooks for high-stakes communications moments.
Situation playbooks · topline to LOE
FDA approval / PDUFA
Complete response letter
Medical congress
Direct-to-patient access
Market access milestone
Pricing / policy scrutiny
Safety issue
Issue / crisis response
Loss of exclusivity
Investor disclosure / 8-K
Internal change / reorganization
AI answer-surface strategy
Watch Ally work a situation · visual walkthroughs
Each card encodes a communications decision pattern specific to pharmaceutical and biotech situations, translating decades of high-stakes pharma and biotech communications judgment into structured guidance Ally applies to the work.
“The difference between a message and a claim. Between a stakeholder and an audience. Between what happened and what it means.”
Build evidence blocks that survive extraction without losing meaning. Keep the message, population, source and qualifier together when a sentence becomes a headline, a reporter’s summary or an AI answer.
In the product · Ally with Research Studio
In the product · counsel before copy
A number moves. Ally stops the quick fix.
Project Aura, a pivotal oncology readout. Fictional simulation.
“Quick fix from biostats: veloctinib median PFS is 9.8 months, not 9.4. Update the release and the talking points before Marcus sees them.”
“Stop — before anyone touches anything: a primary-endpoint median that moves is not a quick fix, it’s a verification event. The 9.4 figure came from locked CSR topline tables and lives in your confirmed strategy and both drafts.”
02 · CAMS · patent pending
Every message, fingerprinted by meaning. One approved message. Every version checked.
Built from what you already have
Point it at your releases, decks and web copy. CAMS extracts your Message Library on day one.
Language atoms
CAMS breaks every approved message into atoms and fingerprints what each one means, not just how it’s worded.
It knows what a line must never become
Every approved atom carries its forbidden variations: the overstatements it must never drift into. Every rewrite is checked against both.
Proof travels with every word
Source, scope and required wording stay attached, so every draft arrives ready for your MLR review.
In the product · semantic and pragmatic fingerprinting
The strategy is not lost down the line. It reaches every audience, in every medium, intact.
The confirmed strategy sets the approved message. Each audience gets its own version, and each asset is shaped for the intermediary that audience trusts. CAMS fingerprints what the message says and what it does, then reads every version back against the parent and the strategy above it.
“Every access route with its own accurate terms. Access supports the story and never becomes a universal price promise.”
Locked by the communications lead“In the US, LUMEVRA is available through HalveronDirect at one flat medicine-only self-pay price: $99 a month for every strength, from September 22.”
Halveron pricing release · MLR Rev 2“In the US, HalveronDirect offers one medicine-only self-pay price at every dose: $99 a month, from September 22.”
Trusted intermediariesCommunity pharmacists · GoodRx · patient creators
“From September 22, US self-pay patients using HalveronDirect pay $99 a month for the medicine at every strength, so titrating the dose does not change the medicine price.”
Trusted intermediariesSTAT · field medical and sales teams · practice managers
“US HalveronDirect medicine-only self-pay price: $99 per month, all strengths, effective September 22.”
Trusted intermediariesFierce Pharma pricing desk · pharmacy partners
“En Estados Unidos, HalveronDirect ofrece el mismo precio de pago directo en todas las dosis: $99 al mes solo por el medicamento, desde el 22 de septiembre.”
Trusted intermediariesSpanish-language radio and TV · promotoras de salud
LUMEVRA and Halveron are fictional. Intermediaries and scores are illustrative. This US HalveronDirect route covers the medicine only; clinical suitability, a prescription, route eligibility and terms apply. Telehealth consultation fees are separate.
03 · Media + AI intelligence
Media + AI intelligence.
GPS compares how the same question is answered as stakeholder circumstances change. Research-built context packs sit separately from the question, helping teams compare answers and cited sources and decide where evidence and media relationships can make a difference.
Built from coverage, not a database
The reporters who actually wrote your story, with the article that earns you the pitch.
Who shapes what AI says
See which sources ChatGPT, Gemini and Perplexity cite when someone asks about your disease or your drug.
Watched overnight
Coverage and AI answers checked every night, with your Morning Desk ready before your day starts.
In the product · a saved Media + AI intelligence read
The New York Times
What self-pay drug prices mean for patients without coverageJul 21, 2026
In litigationSuing OpenAI and MicrosoftFiled Dec 2023 · Amazon license May 2025Reporting is licensed to Amazon AI products, not to OpenAI.
National consumer-health and policy readers
MedPage Today
Clinicians weigh cost conversations as cash-pay options growSep 3, 2026
In litigationParent Ziff Davis suing OpenAIFiled Apr 2025No licensing route into ChatGPT on record.
Physicians and clinical news; prescriber audience
KFF Health News
The fine print behind flat-price prescription offersJun 18, 2026
No dealNo documented relationshipChecked 2026-09-15Stories are free to republish, so copies spread to many outlets AI search can retrieve.
Health-policy and cost reporting; widely republished
Seven rows of twenty-six from a saved read in the LUMEVRA rehearsal. Article titles are illustrative. Publisher–AI records reflect public announcements and court filings, each with its date.
Bring your next readout, launch or crisis. Watch Ally work it.
Thanks. Someone from CommsRx will be in touch to arrange your demo.
That request didn’t go through. Please try again.
Founder-led demos with Abhi Basu. We use this request to arrange your demonstration. Demo request privacy notice · Read the founder’s letter Ally’s Read →
Selected for AI programs
Security and safety
Works inside the tools you use
